Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

628.45INR
23 Oct 2014
Price Change (% chg)

Rs0.05 (+0.01%)
Prev Close
Rs628.40
Open
Rs631.75
Day's High
Rs634.85
Day's Low
Rs625.55
Volume
216,487
Avg. Vol
2,054,069
52-wk High
Rs639.10
52-wk Low
Rs366.50

CIPL.NS

Chart for CIPL.NS

About

Cipla Limited is a pharmaceutical company. During the fiscal year ended March 31, 2012 (fiscal 2012), it introduced a number of new drugs and formulations, such as Adgain (vital nutritional supplement for hair loss); Capnea (caffeine citrate injection and oral solution) for apnoea of prematurity in infants; Caspogin (caspofungin... (more)

Overall

Beta: 0.54
Market Cap (Mil.): Rs504,595.91
Shares Outstanding (Mil.): 802.92
Dividend: 2.00
Yield (%): 0.32

Financials

  CIPL.NS Industry Sector
P/E (TTM): 36.36 33.08 33.86
EPS (TTM): 17.28 -- --
ROI: -- 18.26 17.53
ROE: -- 18.93 18.34
Search Stocks

Drugmaker Cipla to set up manufacturing plant in Iran

MUMBAI - Generic drugmaker Cipla Ltd has agreed to set up a manufacturing plant in Iran, as part of its strategy to boost its presence in the country's $4 billion pharmaceuticals market that is growing at about 13 percent annually.

07 Oct 2014

Indian drugmaker Cipla to set up manufacturing plant in Iran

MUMBAI, Oct 7 - Indian generic drugmaker Cipla Ltd has agreed to set up a manufacturing plant in Iran, as part of its strategy to boost its presence in the country's $4 billion pharmaceuticals market that is growing at about 13 percent annually.

07 Oct 2014

Exclusive - India set to run out of critical free drug for HIV/AIDS programme

NEW DELHI - India could run out of a critical medicine in its free HIV/AIDS drugs programme in three weeks due to bureaucratic bungling, a senior government official said, leaving more than 150,000 sufferers without life-saving drugs for about a month.

01 Oct 2014

UPDATE 2-India caps prices of 36 more drugs to improve access -govt official

* Local firms Cipla, Ranbaxy, Cadila among companies affected

19 Sep 2014

Cipla grants Salix rights for Rifaximin

MUMBAI - Drugmaker Cipla Ltd has agreed to grant U.S.-based Salix Pharmaceuticals Ltd rights relating to the "Rifaximin complexes" patent family controlled by Cipla, the two companies said on Thursday.

18 Sep 2014

India's Cipla grants Salix rights for Rifaximin

MUMBAI, Sept 18 - Indian drugmaker Cipla Ltd has agreed to grant U.S.-based Salix Pharmaceuticals Ltd rights relating to the "Rifaximin complexes" patent family controlled by Cipla, the two companies said on Thursday.

18 Sep 2014

Gilead licenses hepatitis C drug to Cipla, Ranbaxy, five others

NEW DELHI/MUMBAI - U.S. drugmaker Gilead Sciences Inc has licensed its hepatitis C drug Sovaldi to seven India-based drugmakers that will sell far cheaper versions of the $1,000-a-pill medicine in 91 developing nations.

15 Sep 2014

Gilead licenses hepatitis C drug to Cipla, Ranbaxy, 5 others

NEW DELHI/MUMBAI, Sept 15 - U.S. drugmaker Gilead Sciences Inc said on Monday it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.

15 Sep 2014

UPDATE 1-Poor patients in India facing HIV/AIDS drug shortages

* Cipla named as one of firms dropping out of tender process

04 Sep 2014

India's BSE index surges past 27,000 to third consecutive record high

* BSE index gains 0.57 pct; NSE ends 0.69 pct higher * Cipla jumps as much as 8.7 pct after key generic launch By Abhishek Vishnoi MUMBAI, Sept 2 - India's benchmark BSE index on Tuesday surged past the psychologically key level of 27,000 to a third consecutive record high as blue-chips such as HDFC Bank gained after recent data raised hopes about the economy. The BSE milestone comes a day after the broader NSE index surpassed the 8,000 level for the first time, provi

02 Sep 2014

Earnings vs. Estimates

Search Stocks